Respiri (ASX:RSH) share price on watch following FDA approval

The Respiri Ltd (ASX:RSH) share price is on watch after the company announced it's received US FDA clearance for its asthma device and app.

The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app. 

medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

About Respiri  

Respiri is a software-as-a-service (SaaS) company supporting asthma patients to monitor and manage their asthma. The company views that asthma is often under-diagnosed and under-treated, creating a substantial burden to sufferers and their families. 

Respiri has created an eHealth SaaS platform, 'Wheezo', that uses a device and app to measure, record and monitor asthma symptoms. The device records breath sounds over 30 seconds to be analysed in the app. The app has features that allow users to log symptoms, triggers, medication and local environment factors, which can then be used to build a personalised asthma profile to be shared with healthcare professionals. 

The company believes the sub-optimally managed asthma market represents a significant opportunity, with over 340 million people affected globally. 

Respiri share price in focus 

The Respiri share price will be on the radar this morning after the company announced it has received clearance from the US FDA for Wheezo, thus permitting the company to market and sell its product in the US as a class II medical device alongside the Wheezo app. 

Respiri CEO and Managing Director Mr Marjan Mikel commented on clearance: 

The regulatory clearance of Wheezo and our App in the United States represents a highly significant and major milestone for the Company as we continue to expand our regulatory footprint for Wheezo and enter substantial new markets. The FDA is one of the most stringent regulatory bodies in the world and this clearance further validates the efficacy and utility of our Wheezo device and algorithm. To our knowledge [this is] the first time the FDA has cleared a device/mobile application for the detection, recording and changes of wheeze rates. This represents a step-change in technology for patients with respiratory wheeze seeking an effective, replicable and rapid device measurement and associated App that monitors this important measurement of lung function.

Respiri plans to launch in the US market in Q3 2022 with an initial focus on the 60% of children with persistent and severe asthma, representing 3.3 million patients. According to the company, the Wheezo device and app will play a role in providing significant analytical information for patients and their caregivers. 

Respiri highlights the reimbursement codes available from the Centers for Medicare and Medicaid Services (CMS) in the US as a key tailwind for Wheezo. These enable clinicians and qualified medical professionals advising patients on the purchase of the device and associated SaaS fees to receive financial compensation for the time spent and equipment used for patient care delivered remotely. 

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »